UK "agrees to double" adult ECMO capacity in the face of H1N1 threat
This article was originally published in Clinica
Executive Summary
The UK's only provider of adult extracorporeal membrane oxygenation (ECMO) therapy is in discussions with the government over plans by the latter to "double the number of ECMO facilities". Clinica has learnt that an agreement among "all four UK health ministers" to this effect is still "subject to discussions", but the news is a clear acknowledgement of recent evidence of the crucial role that this technology can play in managing the most severe cases of H1N1 infection.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.